US 11,872,220 B2
Methods and compositions for treating B-cell malignancies
Eric Frederik Eldering, Amsterdam (NL); Karoline Kielbassa, Amsterdam (NL); Ulrike Philippar, Antwerp (BE); Andrew Steele, Doylestown, PA (US); Marco Vincent Haselager, Hilversum (NL); and A. P. Kater, Amsterdam (NL)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Aug. 8, 2022, as Appl. No. 17/882,695.
Claims priority of provisional application 63/230,991, filed on Aug. 9, 2021.
Prior Publication US 2023/0074759 A1, Mar. 9, 2023
Int. Cl. A61K 31/4709 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4709 (2013.01) [A61P 35/00 (2018.01)] 32 Claims
 
1. A method of treating a malignancy in a subject in need thereof, said method comprising:
administering to said subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of anti-apoptotic Bcl-2 family protein, wherein the combination therapy is administered to the subject in an amount effective to treat the malignancy in the subject.